Aradigm and CyDex are collaborating to combine products for the treatment of asthma and chronic obstructive pulmonary diseases (COPD).
“Putting together Cydex’ aqueous formulation capabilities with Aradigm’s palm-size AERx Essence inhalation delivery system has the potential to generate a family of attractive novel therapies for asthma and COPD patients,” John Siebert, CEO of CyDex said.
Under the two-year agreement, Aradigm will bear 60% of the costs of development, and CyDex will be responsible for the rest. Third-party licensing and sales revenues will be shared in the same ratio.
The companies will develop and commercialize products containing inhaled corticosteroids, anticholinergics, and beta-2 agonists.